---
document_datetime: 2025-11-05 10:36:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/braftovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: braftovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2653959
conversion_datetime: 2025-12-22 11:52:48.2489
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Braftovi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type II /  | This was an application for a variation | 18/09/2025                          |                                             | SmPC and PL                      | SmPC new text Braftovi SmPC section 4.2: For |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000241083   | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.2 and 5.2 of the SmPC in order to update paediatric information following PIP compliance check (EMEA-C- 001588-PIP01-13- M03 and EMEA-C- 001454-PIP03-15-M03). In addition, the took the opportunity to implement a   | MAH minor correction   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |      | doses and dose reductions for the management of adverse reactions result in plasma exposure similar to that achieved in adults: • Weighing 40 kg and more: the adult dose 45 mg BID with the same dose reduction: 30 mg BID. • Weighing less than 40 kg: 30 mg BID, based on the simulations at lower doses, no dose reduction is proposed, Children under 12 years should not be treated with binimetinib. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000277973 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                        | 16/06/2025 | N/A |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Variation type II / EMA/VR/0000256240 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to update the description of most common adverse drug reactions in the special populations, Elderly, for the indication Colorectal Cancer after an error was | 15/05/2025 |     | SmPC | The most common adverse reactions reported with a higher incidence in patients aged ≥65years compared to patients aged < 65 years included fatigue, decreased appetite, and haemorrhage. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000247451   | This was an application for a group of variations. B.I.a.3 Change in batch size (including batch   | 04/03/2025   | N/A   |
|-----------------------------------------|----------------------------------------------------------------------------------------------------|--------------|-------|